Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
ABSTRACTMultiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and f...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Gut Microbes |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2023.2274126 |
_version_ | 1797320555483889664 |
---|---|
author | Dorota Kujawa Lukasz Laczmanski Slawomir Budrewicz Anna Pokryszko-Dragan Maria Podbielska |
author_facet | Dorota Kujawa Lukasz Laczmanski Slawomir Budrewicz Anna Pokryszko-Dragan Maria Podbielska |
author_sort | Dorota Kujawa |
collection | DOAJ |
description | ABSTRACTMultiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and function of the gut microbiota. In this review, current experimental and clinical evidence is presented for the characteristics of gut dysbiosis found in MS, as well as for its relevant links with the course of the disease and the dysregulated immune response and metabolic pathways involved in MS pathology. Furthermore, therapeutic implications of these investigations are discussed, with a range of pharmacological, dietary and other interventions targeted at the gut microbiome and thus intended to have beneficial effects on the course of MS. |
first_indexed | 2024-03-08T04:40:51Z |
format | Article |
id | doaj.art-5fa345507d8545bdbe1c2672657e13e2 |
institution | Directory Open Access Journal |
issn | 1949-0976 1949-0984 |
language | English |
last_indexed | 2024-03-08T04:40:51Z |
publishDate | 2023-12-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Gut Microbes |
spelling | doaj.art-5fa345507d8545bdbe1c2672657e13e22024-02-08T12:02:07ZengTaylor & Francis GroupGut Microbes1949-09761949-09842023-12-0115210.1080/19490976.2023.2274126Targeting gut microbiota: new therapeutic opportunities in multiple sclerosisDorota Kujawa0Lukasz Laczmanski1Slawomir Budrewicz2Anna Pokryszko-Dragan3Maria Podbielska4Laboratory of Genomics & Bioinformatics, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, PolandLaboratory of Genomics & Bioinformatics, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, PolandDepartment of Neurology, Wroclaw Medical University, Wroclaw, PolandDepartment of Neurology, Wroclaw Medical University, Wroclaw, PolandLaboratory of Microbiome Immunobiology, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, PolandABSTRACTMultiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and function of the gut microbiota. In this review, current experimental and clinical evidence is presented for the characteristics of gut dysbiosis found in MS, as well as for its relevant links with the course of the disease and the dysregulated immune response and metabolic pathways involved in MS pathology. Furthermore, therapeutic implications of these investigations are discussed, with a range of pharmacological, dietary and other interventions targeted at the gut microbiome and thus intended to have beneficial effects on the course of MS.https://www.tandfonline.com/doi/10.1080/19490976.2023.2274126Antibioticsdietdisease-modifying treatmentfecal microbiota transplantationgut microbiomemicrobiota |
spellingShingle | Dorota Kujawa Lukasz Laczmanski Slawomir Budrewicz Anna Pokryszko-Dragan Maria Podbielska Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis Gut Microbes Antibiotics diet disease-modifying treatment fecal microbiota transplantation gut microbiome microbiota |
title | Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis |
title_full | Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis |
title_fullStr | Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis |
title_full_unstemmed | Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis |
title_short | Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis |
title_sort | targeting gut microbiota new therapeutic opportunities in multiple sclerosis |
topic | Antibiotics diet disease-modifying treatment fecal microbiota transplantation gut microbiome microbiota |
url | https://www.tandfonline.com/doi/10.1080/19490976.2023.2274126 |
work_keys_str_mv | AT dorotakujawa targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis AT lukaszlaczmanski targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis AT slawomirbudrewicz targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis AT annapokryszkodragan targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis AT mariapodbielska targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis |